

Patent case: Regeneron Pharmaceuticals v Kymab, United Kingdom

Kluwer Patent Blog
August 16, 2018

Sara Moran

Please refer to this post as: Sara Moran, 'Patent case: Regeneron Pharmaceuticals v Kymab, United Kingdom', Kluwer Patent Blog, August 16 2018, <http://patentblog.kluweriplaw.com/2018/08/16/united-kingdom-regeneron-pharmaceuticals-v-kymab-court-of-appeal-england-wales-civil-division-2018-ewca-civ-1186-23-may-2018/>

Following the Court of Appeal's decision that two of Regeneron's patents were valid and infringed, it refused to grant Kymab permission to appeal to the Supreme Court, but held that the injunction against Kymab should be stayed, subject to certain conditions, whilst Kymab applied directly to the Supreme Court for permission to appeal. The Court also gave directions on the scope of orders for delivery up or destruction of infringing goods, disclosure of information on Kymab's infringing products, and costs.

Case date: 23 May 2018

Case number: [2018] EWCA Civ 1186

Court: Court of Appeal of England and Wales, Civil Division

A full summary of this case has been published on [Kluwer IP Law](#).